Dwinata, M., Putera, D. D., Hasan, I., & Raharjo, M. (2020). SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: A systematic review. Clin Exp Hepatol.
Chicago Style CitationDwinata, Michael, David Dwi Putera, Irsan Hasan, i Monica Raharjo. "SGLT2 Inhibitors for Improving Hepatic Fibrosis and Steatosis in Non-alcoholic Fatty Liver Disease Complicated With Type 2 Diabetes Mellitus: A Systematic Review." Clin Exp Hepatol 2020.
Cita MLADwinata, Michael, David Dwi Putera, Irsan Hasan, i Monica Raharjo. "SGLT2 Inhibitors for Improving Hepatic Fibrosis and Steatosis in Non-alcoholic Fatty Liver Disease Complicated With Type 2 Diabetes Mellitus: A Systematic Review." Clin Exp Hepatol 2020.